These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

90 related items for PubMed ID: 9676838

  • 1. Antitumor activity of TP3(anti-p80)-pokeweed antiviral protein immunotoxin in hamster cheek pouch and severe combined immunodeficient mouse xenograft models of human osteosarcoma.
    Ek O, Waurzyniak B, Myers DE, Uckun FM.
    Clin Cancer Res; 1998 Jul; 4(7):1641-7. PubMed ID: 9676838
    [Abstract] [Full Text] [Related]

  • 2. In vitro and in vivo cytotoxicity of an anti-osteosarcoma immunotoxin containing pokeweed antiviral protein.
    Anderson PM, Meyers DE, Hasz DE, Covalcuic K, Saltzman D, Khanna C, Uckun FM.
    Cancer Res; 1995 Mar 15; 55(6):1321-7. PubMed ID: 7882330
    [Abstract] [Full Text] [Related]

  • 3. In vivo anti-leukemic efficacy of anti-CD7-pokeweed antiviral protein immunotoxin against human T-lineage acute lymphoblastic leukemia/lymphoma in mice with severe combined immunodeficiency.
    Gunther R, Chelstrom LM, Finnegan D, Tuel-Ahlgren L, Irvin JD, Myers DE, Uckun FM.
    Leukemia; 1993 Feb 15; 7(2):298-309. PubMed ID: 7678882
    [Abstract] [Full Text] [Related]

  • 4. Effective immunochemotherapy of human t(4;11) leukemia in mice with severe combined immunodeficiency (SCID) using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin plus cyclophosphamide.
    Jansen B, Kersey JH, Jaszcz WB, Gunther R, Nguyen DP, Chelstrom LM, Tuel-Ahlgren L, Uckun FM.
    Leukemia; 1993 Feb 15; 7(2):290-7. PubMed ID: 7678881
    [Abstract] [Full Text] [Related]

  • 5. In vivo toxicity, pharmacokinetics, and antileukemic activity of TXU (anti-CD7)-pokeweed antiviral protein immunotoxin.
    Waurzyniak B, Schneider EA, Tumer N, Yanishevski Y, Gunther R, Chelstrom LM, Wendorf H, Myers DE, Irvin JD, Messinger Y, Ek O, Zeren T, Langlie MC, Evans WE, Uckun FM.
    Clin Cancer Res; 1997 Jun 15; 3(6):881-90. PubMed ID: 9815763
    [Abstract] [Full Text] [Related]

  • 6. TP-3 immunotoxins improve antitumor activity in mice with osteosarcoma.
    Onda M, Bruland ØS, Pastan I.
    Clin Orthop Relat Res; 2005 Jan 15; (430):142-8. PubMed ID: 15662316
    [Abstract] [Full Text] [Related]

  • 7. Establishment of a human t(4;11) leukemia in severe combined immunodeficient mice and successful treatment using anti-CD19 (B43)-pokeweed antiviral protein immunotoxin.
    Jansen B, Uckun FM, Jaszcz WB, Kersey JH.
    Cancer Res; 1992 Jan 15; 52(2):406-12. PubMed ID: 1370213
    [Abstract] [Full Text] [Related]

  • 8. An Epstein-Barr virus-infected lymphoblastoid cell line (D430B) that grows in SCID-mice with the morphologic features of a CD30+ anaplastic large cell lymphoma, and is sensitive to anti-CD30 immunotoxins.
    Tazzari PL, de Totero D, Bolognesi A, Testoni N, Pileri S, Roncella S, Reato G, Stein H, Gobbi M, Stirpe F.
    Haematologica; 1999 Nov 15; 84(11):988-95. PubMed ID: 10553158
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetic features, immunogenicity, and toxicity of B43(anti-CD19)-pokeweed antiviral protein immunotoxin in cynomolgus monkeys.
    Uckun FM, Yanishevski Y, Tumer N, Waurzyniak B, Messinger Y, Chelstrom LM, Lisowski EA, Ek O, Zeren T, Wendorf H, Langlie MC, Irvin JD, Myers DE, Fuller GB, Evans W, Gunther R.
    Clin Cancer Res; 1997 Mar 15; 3(3):325-37. PubMed ID: 9815689
    [Abstract] [Full Text] [Related]

  • 10. Anti-CD7 antibody and immunotoxin treatment of human CD7(+)T-cell leukaemia is significantly less effective in NOD/LtSz-scid mice than in CB.17 scid mice.
    Flavell DJ, Warnes SL, Noss AL, Flavell SU.
    Br J Cancer; 2000 Dec 15; 83(12):1755-61. PubMed ID: 11104577
    [Abstract] [Full Text] [Related]

  • 11. Treatment of human B-cell precursor leukemia in SCID mice using a combination of the investigational biotherapeutic agent B43-PAP with cytosine arabinoside.
    Messinger Y, Yanishevski Y, Avramis VI, Ek O, Chelstrom LM, Gunther R, Myers DE, Irvin JD, Evans W, Uckun FM.
    Clin Cancer Res; 1996 Sep 15; 2(9):1533-42. PubMed ID: 9816330
    [Abstract] [Full Text] [Related]

  • 12. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency.
    Uckun FM, Manivel C, Arthur D, Chelstrom LM, Finnegan D, Tuel-Ahlgren L, Irvin JD, Myers DE, Gunther R.
    Blood; 1992 May 01; 79(9):2201-14. PubMed ID: 1373967
    [Abstract] [Full Text] [Related]

  • 13. Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin.
    Flavell DJ, Boehm DA, Noss A, Warnes SL, Flavell SU.
    Br J Cancer; 2001 Feb 01; 84(4):571-8. PubMed ID: 11207056
    [Abstract] [Full Text] [Related]

  • 14. Host-mediated antibody-dependent cellular cytotoxicity contributes to the in vivo therapeutic efficacy of an anti-CD7-saporin immunotoxin in a severe combined immunodeficient mouse model of human T-cell acute lymphoblastic leukemia.
    Flavell DJ, Warnes S, Noss A, Flavell SU.
    Cancer Res; 1998 Dec 15; 58(24):5787-94. PubMed ID: 9865737
    [Abstract] [Full Text] [Related]

  • 15. Anti-CD30 (BER=H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID mice.
    Terenzi A, Bolognesi A, Pasqualucci L, Flenghi L, Pileri S, Stein H, Kadin M, Bigerna B, Polito L, Tazzari PL, Martelli MF, Stirpe F, Falini B.
    Br J Haematol; 1996 Mar 15; 92(4):872-9. PubMed ID: 8616080
    [Abstract] [Full Text] [Related]

  • 16. Effective immunochemotherapy of CALLA+C mu+ human pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19) pokeweed antiviral protein immunotoxin plus cyclophosphamide.
    Uckun FM, Chelstrom LM, Finnegan D, Tuel-Ahlgren L, Manivel C, Irvin JD, Myers DE, Gunther R.
    Blood; 1992 Jun 15; 79(12):3116-29. PubMed ID: 1375841
    [Abstract] [Full Text] [Related]

  • 17. Immunological and biological stability of immunotoxins in vivo as studied by the clearance of disulfide-linked pokeweed antiviral protein-antibody conjugates from blood.
    Ramakrishnan S, Houston LL.
    Cancer Res; 1985 May 15; 45(5):2031-6. PubMed ID: 3986759
    [Abstract] [Full Text] [Related]

  • 18. The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
    Flavell DJ, Warnes SL, Bryson CJ, Field SA, Noss AL, Packham G, Flavell SU.
    Br J Haematol; 2006 Jul 15; 134(2):157-70. PubMed ID: 16771848
    [Abstract] [Full Text] [Related]

  • 19. CNS activity of Pokeweed anti-viral protein (PAP) in mice infected with lymphocytic choriomeningitis virus (LCMV).
    Uckun FM, Rustamova L, Vassilev AO, Tibbles HE, Petkevich AS.
    BMC Infect Dis; 2005 Feb 22; 5():9. PubMed ID: 15725345
    [Abstract] [Full Text] [Related]

  • 20. Biotherapy for xenografted human central nervous system leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin.
    Gunther R, Chelstrom LM, Tuel-Ahlgren L, Simon J, Myers DE, Uckun FM.
    Blood; 1995 May 01; 85(9):2537-45. PubMed ID: 7537120
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.